Review Article

RNA Polymerase II Elongation at the Crossroads of Transcription and Alternative Splicing

Manuel de la Mata,1,2 Manuel J. Muñoz,1 Mariano Alló,1 Juan Pablo Fededa,1,3 Ignacio E. Schor,1 and Alberto R. Kornblihtt1

1Laboratorio de Fisiología y Biología Molecular, Departamento de Fisiología, Biología Molecular, y Celular, IFIBYNE-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, C1428EHA Buenos Aires, Argentina
2Friedrich Miescher Institute for Biomedical Research, 4002 Basel, Switzerland
3Department of Biology, Institute of Biochemistry, ETH Zurich, 8093 Zurich, Switzerland

Correspondence should be addressed to Alberto R. Kornblihtt, ark@fbmc.fcen.uba.ar

Received 15 June 2011; Accepted 23 June 2011

Academic Editor: Carles Sune

Copyright © 2011 Manuel de la Mata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The elongation phase of transcription lies at the core of several simultaneous and coupled events leading to alternative splicing regulation. Although underestimated in the past, it is at this phase of the transcription cycle where complexes affecting the transcription machinery itself, chromatin structure, posttranscriptional gene regulation and pre-mRNA processing converge to regulate each other or simply to consolidate higher-order complexes and functions. This paper focuses on the multiple processes that take place during transcription elongation which ultimately regulate the outcome of alternative splicing decisions.

1. Introduction

Regulation of gene expression was originally conceived as a hierarchy of steps linked together on a time scale and physically separated in different cell compartments in accordance with the central dogma of biology. This concept has long been abandoned, with a significant accumulation of evidence describing an extensive network of events, encompassing transcription, mRNA processing, chromatin regulation, and posttranscriptional gene regulation, which take place simultaneously and in a mutually regulated or coupled manner [1, 2]. Distinctions between complexes and processes governing gene expression have been blurred to a large extent, adding complexity to the ever-increasing fraction of genes subjected to alternative promoter usage, alternative splicing (AS) (>90% genes), alternative polyadenylation, editing, and posttranscriptional gene silencing by small RNAs [3, 4]. Additionally, this complexity takes a new dimension when studied in the context of chromatin and its regulation upon gene expression (for reviews, see [5–7]). This paper will focus on the main features of coupling between transcriptions elongation and splicing, and its implications on AS regulation.

2. The Benefits of Coupling

Initial visualization of Drosophila-embryo nascent transcripts by electron microscopy, showed that splicing can occur cotranscriptionally [8]. This was later directly demonstrated for the human dystrophin gene [9], which spans 2400 kb and can take 16 hr to complete transcription. More recently, a quantitative study of the c-Src and fibronectin mRNAs compared chromatin-bound and nucleoplasmic RNA fractions. There, it was shown that most introns are excised efficiently in the chromatin-bound fractions, with a gradient of cotranscriptional splicing efficiency decreasing from promoter-proximal to promoter-distal introns, that is, the direction of transcription [10].

One implication of the cotranscriptional nature of splicing is that the two processes can be coupled. In a broad sense, coupling implies that the involved processes can happen efficiently only as the result of their combined action, even
for processes that are constitutive and non-regulated. For instance, whereas both transcription and splicing can take place independently at low efficiency as in vitro reactions, it is only in vivo or in coupled in vitro systems where maximal efficiency can be achieved [11–16]. Cotranscriptional processing is necessary to allow for coupling between transcription and splicing, although it does not necessarily guarantee it. There are examples of both cotranscriptional splicing that seems to be uncoupled, as well as purely posttranscriptional splicing [17–20]. Noteworthy, the consequences of the different types of splicing can be considerable; whereas cotranscriptional splicing can be regulated by mechanisms dependent on transcription, posttranscriptional splicing can be subjected to additional regulatory mechanisms linked to events downstream of transcription (e.g., RNA export) [20]. However, cotranscriptional splicing seems to predominate for most introns in mammalian genes [10, 17, 20–23] pointing at an evolutionary conserved role in allowing for coupling of transcription and splicing. Cotranscriptional splicing is more efficient than posttranscriptional splicing by driving nascent pre-mRNAs to the association with spliceosome components [24, 25] and splicing regulatory factors, such as serine/arginine-rich (SR) proteins [22]. This allows for different levels of regulation of AS and prevents backhybridization of the nascent pre-mRNA to the DNA template strand, which can cause genome instability [26, 27]. Even in the case of posttranscriptional splicing, coupling with transcription can be determinant for AS regulation. Since pre-mRNA splicing is a multistep reaction, it is possible that commitment to splicing takes place cotranscriptionally during early splice-site recognition, while completion of the splicing reaction occurs posttranscriptionally [20, 28, 29], consistent with the fact that introns are not necessarily removed in the exact order that they are transcribed [17, 30–32]. This mechanism, which can be viewed as a cotranscriptional commitment rather than a cotranscriptional catalysis, tends to apply largely to splicing and not to other RNA-processing events like capping and cleavage/polyadenylation [33–37]. Intermediate scenarios are also possible, with both splicing commitment and catalysis taking place cotranscriptionally but not following a strict 5’ to 3’ direction of intron removal [10, 38].

Another implication of cotranscriptional splicing is that it allows for a bidirectional coupling of the two processes [1, 20, 39, 40]. For instance, the splicing machinery can reciprocally affect transcription in different ways by either stimulating transcriptional elongation [41, 42], transcriptional initiation [43, 44] and, as recently shown in yeast, by imposing a transient pausing checkpoint around the 3’ end of introns and on terminal exons [45, 46]. This bidirectional feedback might in turn reinforce splicing efficiency, conferring important advantages for gene expression. Nevertheless, reciprocal coupling might not be a widespread general phenomenon considering that elongation kinetics seems to be independent of splicing in some model genes [47]. This highlights the possibility that specific exon-intron architectures and/or cis-acting sequences might be required for reciprocal coupling to occur.

Despite all the seemingly clear advantages of cotranscriptional over posttranscriptional splicing, particularly in allowing for coupling, the true proportions of these two modes of splicing in mammals still await to be determined on a genome-wide scale. It will be interesting to use global approaches to answer this question, which might have profound implications in reorienting our current research and on our understanding of the regulation of AS.

3. Early Discoveries

In our current view, the regulation of AS is the result of the combined action of splicing factors acting on splicing enhancers and silencers, regulatory secondary structure motifs of mRNAs, and the coupling with RNA polymerase II (Pol II) transcription [22, 48–51]. An early indication for coupling was the finding that promoter identity affects splicing decisions independently of the strength of the promoter, opposing the classical view whereby promoters are limited to affect transcription levels ([52–56], for review, see [57]). Different promoters, such as those of the α-globin and fibronectin (FN) genes, were shown to induce a 10-fold difference in inclusion of the human FN alternative exon 33 (E33, also referred to as EDI or EDA) when driving its expression from reporter minigenes in transiently transfected mammalian cells [52, 53] (Figure 1).

One implication of the promoter effect on AS is that splicing factors could regulate AS through promoters. Cell-specific AS events could then arise from cell-specific promoter occupation rather than from the differential abundance of ubiquitous splicing factors. Under physiological conditions, promoter architecture could then control AS through the differential occupation by different transcription factors. Supporting this hypothesis, evidence shows that transcriptional activators and coactivators, with different effects on Pol II, indeed affect AS differentially [58, 59].

4. The Kinetics of Coupling

Transcription appears to influence pre-mRNA splicing through at least two independent modes: by kinetically coupling the processing reactions, where the rate of Pol II elongation influences the outcome of the alternative events [60, 61], and by physically and functionally recruiting mRNA processing factors to the transcription machinery, in particular to Pol II’s carboxyterminal domain (CTD) [13, 62–65]. In fact, recruitment of splicing factors to sites of transcription is dependent on RNA Pol II CTD [66] and deletion of the CTD impairs capping, cleavage/polyadenylation, and splicing of the b-globin transcript [34]. Here we provide a view of the kinetic mode of coupling, although accumulated evidence supports that both modes can operate simultaneously in a nonmutually exclusive manner (for reviews on the recruitment mode of coupling, see [2, 65, 67]).

It should be pointed out that transcription itself is a complex multistep and regulated process, organized as a transcription cycle, with each step subjected to extensive regulation [68]. However, it is mainly at the elongation step of transcription where most of the connections between
the transcription and splicing machineries actually occur. A role for Pol II elongation on AS was suggested before the finding of the promoter effect [69] and was later supported by several lines of evidence. Eperon et al. [69] showed that, in contrast to in vitro conditions, ongoing RNA synthesis in vivo affects the potential secondary structure of long—but not that of short—RNA substrates, which in turn affects splicing, pointing at a kinetic link between transcription and splicing. Additional evidence came from experiments in which RNA Pol II’s local pausing caused by elements inserted into the tropomyosin gene, promoted higher inclusion of tropomyosin exon 3 [60]. However, more conclusive evidence for a role of elongation on AS regulation was shown in a series of reports demonstrating that several factors globally impacting Pol II elongation also affect AS. (i) Replication of AS reporter minigenes greatly stimulates FN E33 inclusion, and is counteracted by trichostatin A (TSA), a potent inhibitor of histone deacetylation considered to drive chromatin into an “open” state. This suggested that replication conveys a more compact chromatin structure to the template, thus slowing elongation and leading to higher E33 inclusion [70]. (ii) Drugs known to inhibit elongation, such as DRB [58, 70], flavopiridol, or camptothecin [38], favor E33 inclusion. (iii) Transcriptional activation by VP16, a factor that promotes both initiation and elongation, decreases E33 inclusion while Sp1, acting only on initiation, has no effect on E33 inclusion [58]. (iv) The presence of the SV40 transcriptional enhancer near a promoter stimulates Pol II elongation and provokes a 3–10-fold reduction in FN E33 inclusion independently of the promoter used [71]. (v) Slow mutants of RNA Pol II increase FN E33 inclusion in human cells, affect AS of the endogenous gene ultrabithorax (Ubx) in Drosophila, and modulate the inclusion of an artificially created alternative exon in yeast [61, 72]. (vi) DNA-damage signaling triggered by UV irradiation affects the AS of fibronectin, caspase 9, Bcl-x, and other human genes by inducing hyperphosphorylation of Pol II CTD and blocking Pol II elongation [73]. These data are in agreement with a “first come, first served” model for regulation of AS [74] (Figure 2). One interpretation of this model is that slow elongation favors the removal of the intron upstream of an alternative cassette exon before removal of the downstream intron. Alternatively, slow elongation would favor recruitment of splicing factors to the upstream intron before the downstream intron is synthesized. Once commitment to include the exon is achieved, the order of intron removal becomes irrelevant (Figure 2). The latter interpretation is supported by recent evidence showing a preferential removal of the intron downstream of the FN cassette exon 33 before the upstream intron has been removed [38]. Most importantly, whereas cis-acting mutations and trans-acting factors that upregulate E33 inclusion alter the relative order of intron removal, elongation slowdown also induces higher E33 inclusion without affecting the order of intron removal, suggesting that slow elongation favors commitment to exon inclusion during spliceosome assembly [38]. In light of these findings, “first served” would not be equivalent to “first excised” but to “first committed,” in agreement with the observed preferential cotranscriptional reciprocity of spliceosome recruitment rather than catalysis. The control of elongation on AS is not restricted to a few cases. Recent data confirms and extends the findings of elongation control on AS using a global approach based on AS microarray profiling [48]. This study demonstrates that a variety of conditions that impact Pol II elongation, including drug treatments (DRB and camptothecin), Pol II mutants that inhibit elongation (slow and CTD phosphorylation Pol II mutants), and cellular stress (UV irradiation, known to impact Pol II elongation), globally affect both the mRNA levels and AS of a significant number of the genes. Moreover, the largest statistically significant fraction of affected genes showed a concomitant decrease in steady-state mRNA levels with increase in exon inclusion levels, coincident with many of the examples previously reported [60, 61, 70, 72, 73, 75, 76]. Nevertheless, there was also a smaller but significant number of genes displaying decreased mRNA levels with
decreased exon inclusion levels [48], consistent with the idea that inhibition of Pol II elongation can lead to increased exon inclusion as well as increased exon skipping depending on the underlying splicing regulatory mechanism involved in each case [55, 61]. Pol II’s elongation-dependent changes in AS regulation also display a high preference to modulate the expression levels of genes involved in RNA metabolism, including pre-mRNA splicing factors and other RNA binding proteins. Interestingly, about one-third of those genes contain AS events that introduce a premature termination codon (PTC) when spliced into the mature mRNA, subsequently leading to nonsense-mediated mRNA decay (NMD) [48]. This represents another example of evolutionarily conserved elongation-coupled events, acting together to coordinate the levels or RNA binding proteins with their steady-state mRNA levels.

5. Elongation Links to Chromatin

The promoter effect, together with the kinetic, physical, and functional coupling modes of transcription and AS, immediately shifted the attention to other factors thought to be restricted to transcriptional regulation, such as the chromatin structure. It soon became clear that the unanticipated complexity of splicing regulation could not be explained solely based on the current models, which lacked a clear connection to in vivo situations. Chromatin is the natural substrate upon which transcriptional regulation acts in vivo, and major discoveries have recently pointed at chromatin structure and post-translational histone modifications as key regulators of AS.

The chromatin role on AS regulation is broad, involving both direct (elongation-independent) interactions with the splicing machinery and effects on AS through changes in transcription elongation. Here, we concentrate on the later, although recent findings on the direct roles of chromatin on splicing have significantly changed our view of how exon-intron architecture is achieved by intimately linking nucleosome to exon structure ([77–84], for reviews, see [5–7]. In fact, genome-wide mapping of nucleosome positioning on exons at the DNA level may shed light on one of the most striking puzzles in the field of splicing, that is, how does the splicing machinery recognizes, with high fidelity, short exons (on average 150 bp) “floating” in a “sea” of introns (on average 5.4 kbp), an exon-intron architecture typical of vertebrate genes [85, 86]. Notably, the average size of a mammalian exon is similar to the length of DNA wrapped around a nucleosome, suggesting a conserved function for the nucleosome in exon definition [79, 80, 82]. According to the exon definition model, originally postulated by S. M. Berget [87], the spliceosome and auxiliary factors achieve this recognition by preferentially assembling on 3′ and 5′ sites paired across exons and not across introns (i.e., not following an intron definition mode of recognition, typical in lower eukaryotes like yeast). This favors exon recognition and acts as a selective force for short exon size. As described below, nucleosome positioning on exons may help in exon definition by creating roadblocks for Pol II elongation that
provide longer time for cotranscriptional recognition of
splice sites in the nascent pre-mRNA.

6. Chromatin Structure in Coupling

A role for chromatin in the coupling of elongation with AS
was first suggested with the finding that two copies of the
same adenovirus genome, either unreplicated or replicated
in the same nucleus, gave rise to different alternatively
spliced RNAs [57]. It was then speculated that the chromatin
organization acquired after replication was more compact,
with a subsequent reduction in Pol II elongation rates and
more time to assemble splicing complexes at a suboptimal
upstream 5′ splice site, thus favoring its use compared
to the downstream 5′ splice site. This was confirmed
by the finding that FN E33 inclusion is sensitive to the
replication-mediated chromatinization status of the reporter
plasmid [58, 70] (Figure 3(a). See above). Both in plants
and humans genes, RNA Pol II distribution correlates with
nucleosome deposition with preferential accumulation at
exons relative to introns [79, 80, 83, 88], consistent with
nucleosomes acting as barriers that locally modulate RNA
Pol II density by inducing its pausing [89, 90]. This could
in turn modulate splicing efficiency, in agreement with RNA
Pol II being more highly enriched at alternatively spliced
exons than at constitutive ones [88]. Nucleosome density
also varies according to splice site strength, with stronger
positioning of nucleosomes in included alternatively spliced
exons than excluded ones [80] and stronger positioning at
exons defined by weaker splice sites [81, 82]. Consistent
with these results, overexpression of the ATPase-dependent
chromatin-remodeling complex SWI/SNF subunit Brm in
human cells, induces accumulation of Pol II with a modified
CTD phosphorylation pattern on regions encoding variant
exons of the CD44 gene and causes increased inclusion of
these exons into mature mRNA [91].

7. Histone Modifications in Coupling

Histone modifications have emerged as major regulators of
AS by either impacting the coupling of elongation with AS
or by direct means such as recruiting splicing factors to the
nascent pre-mRNA [7]. An indication for a role of histone
modifications in the coupling of elongation with AS was the
observation that treatment of cells with the histone deacetylase-inhibitor TSA induces skipping of the alternatively
spliced fibronectin E33 and the neural cell adhesion molecule (NCAM) exon 18 [58, 75, 76]. In a more physiological context, depolarization of neuronal cells increases H3K9 acetylation and H3K36 methylation locally around the alternatively spliced exon 18 of NCAM which correlates with increased exon skipping [76] (Figure 3(b)). Interestingly, no changes in histone acetylation were observed at the NCAM promoter, suggesting that this reversible effect may be due to an intragenic and local modulation of the RNA Pol II elongation rate [76]. For instance, acetylated and open chromatin would induce fast Pol II elongation and skipping of the alternative exon. In line with these observations, targeting of an intronic sequence downstream of the alternatively spliced E33 of fibronectin with small interfering RNAs induces local heterochromatinization and increased E33 inclusion without changes in general transcription levels [75] (Figure 3(c)). In addition, inhibition of histone deacetylation, DNA methylation, H3K9 methylation, and downregulation of heterochromatin protein 1a (HP1α) abolish the siRNA-mediated effect on exon E33 splicing [75], suggesting a role of these modifications in AS regulation. Considering the multiple evidence for the involvement of chromatin in siRNA effects on splicing, this mechanism has been referred to as TGS-AS for transcriptional gene-silencing-regulated AS [92] (Figure 3(c)).

Several other epigenetic modifications, including DNA methylation, may also directly or indirectly act via histone modifications to affect splice site decisions [83, 93, 94]. This adds to the additional mechanism involving direct physical crosstalk between chromatin and the splicing machinery via an adaptor complex [7, 95, 96].

8. Conclusions and Outlook

The fact that transcriptional elongation is largely connected to pre-mRNA processing and particularly to AS regulation has boosted extensive efforts to understand its mechanisms and physiological implications. The link to chromatin seems to be the natural way in which elongation and splicing are truly engaged and might indeed explain the poorly understood mechanisms by which tissue- and cell-type-specific AS patterns are established, propagated, and maintained. Although some cell- and tissue-specific differences in expression of constitutive splicing factors have been reported [97], it is tempting to speculate that, in analogy to the histone code mechanisms used to specify gene expression, a histone-based system may also encode information that specifies cell- and tissue-specific AS patterns. As recently proposed, this would provide an epigenetic memory for splicing decisions likely to beheritable during proliferation and susceptible to modification along differentiation, without the need for major changes in the AS rules at each step of differentiation [7]. Nevertheless, it still remains to be determined whether the effects of histone modification on RNA processing are heritable and therefore authentic epigenetic modifications or whether they are just transient modulators.

Given the bidirectional nature of coupling, it is conceivable that splicing might reciprocally feed back on the chromatin structure via affecting the transcription machinery. In fact, besides recruiting splicing regulators such as SR proteins or U2 snRNP subunits [25, 64], Pol II can interact with histone modifiers such as the histone 3 lysine 36 (H3K36) methyltransferase Set2 [98], known, for example, to regulate histone deacetylation and prevent inappropriate initiation within the body of transcribed genes [99]. This interesting possibility would build up on the notion that transcription, chromatin, and splicing are intimately dependent on each other.

Future directions of the field will most likely aim at a more comprehensive view on the histone modifications role in AS. Histone modifications must be comprehensively mapped on a genome-wide scale in multiple cell types and tissues and compared to global AS patterns. New candidate players will be most likely be studied, such as noncoding RNAs recently shown to be involved in heterochromatin structure and associated with AS regulation [100, 101]. Ultimately, a better understanding of the multiple links between transcription and splicing will head the way to decipher the complexity of gene expression both in physiological and pathological conditions.

Acknowledgments

The authors thank Valeria Buggiano and the rest of the members of the Kornblihtt and Srebrow laboratories for their invaluable help. Work in their laboratory is supported by grants to A. R. Kornblihtt from the Agencia Nacional de Promoción de Ciencia y Tecnología de Argentina, the Universidad de Buenos Aires, and the European Alternative Splicing Network (EURASNET). A. R. Kornblihtt is a career investigator at the Consejo Nacional de Investigaciones Científicas y Técnicas of Argentina (CONICET) and an international research scholar of the Howard Hughes Medical Institute.

References

[1] A. R. Kornblihtt, M. de la Mata, J. P. Fededa, M. J. Muñoz, and G. Nogués, “Multiple links between transcription and splicing,” RNA, vol. 10, no. 10, pp. 1489–1498, 2004.
[2] S. Pandit, D. Wang, and X. D. Fu, “Functional integration of transcriptional and RNA processing machineries,” Current Opinion in Cell Biology, vol. 20, no. 3, pp. 260–265, 2008.
[3] Q. Pan, O. Shai, L. J. Lee, B. J. Frey, and B. J. Blencowe, “Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing,” Nature Genetics, vol. 40, no. 12, pp. 1413–1415, 2008.
[4] E. T. Wang, R. Sandberg, S. Luo et al., “Alternative isoform regulation in human tissue transcriptomes,” Nature, vol. 456, no. 7221, pp. 470–476, 2008.
[5] I. E. Schor, M. Allo, and A. R. Kornblihtt, “Intragenic chromatin modifications: a new layer in alternative splicing regulation,” Epigenetics, vol. 5, no. 3, pp. 174–179, 2010.
[6] M. Allo, I. E. Schor, M. J. Muñoz et al., “Chromatin and alternative splicing,” Cold Spring Harbor Laboratory of Quantitative Biology, vol. 75, pp. 103–111, 2010.
[7] R. F. Luco, M. Allo, I. E. Schor, A. R. Kornblihtt, and T. Misteli, “Epigenetics in alternative pre-mRNA splicing,” Cell, vol. 144, no. 1, pp. 16–26, 2011.
[8] A. L. Beyer and Y. N. Osheim, “Splice site selection, rate of splicing, and alternative splicing on nascent transcripts,” Genes & Development, vol. 2, no. 6, pp. 754–765, 1988.

[9] C. N. Tennyson, H. J. Klast, and R. G. Woron, “The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced,” Nature Genetics, vol. 9, no. 2, pp. 184–190, 1995.

[10] A. Pandya-Jones and D. L. Black, “Co-transcriptional splicing of constitutive and alternative exons,” RNA, vol. 15, no. 10, pp. 1896–1908, 2009.

[11] S. Ghosh and M. A. García-Blanco, “Coupled in vitro synthesis and splicing of RNA polymerase II transcripts,” RNA, vol. 6, no. 9, pp. 1325–1334, 2000.

[12] I. Wetterberg, J. Zhao, S. Masich, L. Wieslander, and U. Skoglund, “In situ transcription and splicing in the Balbiani ring 3 gene,” The EMBO Journal, vol. 20, no. 10, pp. 2564–2574, 2001.

[13] G. Bird, D. A. R. Zorio, and D. L. Bentley, “RNA polymerase II carboxy-terminal domain phosphorylation is required for cotranscriptional pre-mRNA splicing and 3′-end formation,” Molecular and Cellular Biology, vol. 24, no. 20, pp. 8963–8969, 2004.

[14] B. I. Natalizio and M. A. García-Blanco, “In vitro coupled transcription splicing,” Methods, vol. 37, no. 4, pp. 314–322, 2005.

[15] R. Das, K. Dufu, B. Romney, M. Feldt, M. Elenko, and R. Reed, “Functional coupling of RNAPII transcription to spliceosome assembly,” Genes and Development, vol. 20, no. 9, pp. 1100–1109, 2006.

[16] M. I. Hicks, C. R. Yang, M. V. Kotlajich, and K. J. Hertel, “Linking splicing to Pol II transcription stabilizes pre-mRNAs and influences splicing patterns,” PLoS Biology, vol. 4, no. 6, article e147, 2006.

[17] G. Bauren and L. Wieslander, “Splicing of Balbiani ring 1 gene pre-mRNA occurs simultaneously with transcription,” Cell, vol. 76, no. 1, pp. 183–192, 1994.

[18] C. Lahrenci, A. M. Källman, N. Fong, D. L. Bentley, and M. Öhman, “RNA editing and alternative splicing: the importance of co-transcriptional coordination,” EMBO Reports, vol. 7, no. 3, pp. 303–307, 2006.

[19] D. Lazarev and J. L. Manley, “Concurrent splicing and transcription are not sufficient to enhance splicing efficiency,” RNA, vol. 13, no. 9, pp. 1546–1557, 2007.

[20] J. Han, J. Xiong, D. Wang, and X.-D. Fu, “Pre-mRNA splicing: Where and when in the nucleus,” Trends in Cell Biology, vol. 21, no. 6, pp. 336–343, 2011.

[21] G. Zhang, K. L. Taneja, R. H. Singer, and M. R. Green, “Localization of pre-mRNA splicing in mammalian nuclei,” Nature, vol. 372, no. 6508, pp. 809–812, 1994.

[22] R. Das, J. Yu, Z. Zhang et al., “SR proteins function in coupling RNAPII transcription to pre-mRNA splicing,” Molecular Cell, vol. 26, no. 6, pp. 867–881, 2007.

[23] J. Singh and R. A. Padgett, “Rates of in situ transcription and splicing in large human genes,” Nature Structural and Molecular Biology, vol. 16, no. 11, pp. 1128–1133, 2009.

[24] S. A. Lacadie, D. F. Tardiff, S. Kadener, and M. Rosbash, “In vivo commitment to yeast cotranscriptional splicing is sensitive to transcription elongation mutants,” Genes and Development, vol. 20, no. 15, pp. 2055–2066, 2006.

[25] I. Listerman, A. K. Supra, and K. M. Neugebauer, “Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells,” Nature Structural and Molecular Biology, vol. 13, no. 9, pp. 815–822, 2006.

[26] X. Li and J. L. Manley, “Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability,” Cell, vol. 122, no. 3, pp. 365–378, 2005.

[27] A. Aguilera and B. Gómez-González, “Genome instability: a mechanistic view of its causes and consequences,” Nature Reviews Genetics, vol. 9, no. 3, pp. 204–217, 2008.

[28] M. J. Moore, E. M. Schwartzfarb, P. Silver, and M. C. Yu, “Differential recruitment of the splicing machinery during transcription predicts genome-wide patterns of mRNA splicing,” Molecular Cell, vol. 24, no. 6, pp. 903–915, 2006.

[29] D. F. Tardiff, S. A. Lacadie, and M. Rosbash, “A genome-wide analysis indicates that yeast pre-mRNA splicing is predominantly posttranscriptional,” Molecular Cell, vol. 24, no. 6, pp. 917–929, 2006.

[30] M. F. LeMaire and C. S. Thummel, “Splicing precedes polyadenylation during Drosophila E74A transcription,” Molecular and Cellular Biology, vol. 10, no. 11, pp. 6059–6063, 1990.

[31] O. Kessler, Y. Jiang, and L. A. Chasin, “Order of intron removal during splicing of endogenous adenine phosphoribosyltransferase and dihydrofolate reductase pre-mRNA,” Molecular and Cellular Biology, vol. 13, no. 10, pp. 6211–6222, 1993.

[32] C. Attanasio, A. David, and M. Neerman-Arbez, “Outcome of donor splice site mutations accounting for congenital afibrinogenemia reflects order of intron removal in the fibrinogen alpha gene (FGA),” Blood, vol. 101, no. 5, pp. 1851–1856, 2003.

[33] S. McCracken, N. Fong, E. Rosonina et al., “5′-capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II,” Genes and Development, vol. 11, no. 24, pp. 3306–3318, 1997.

[34] S. McCracken, N. Fong, K. Yankulov et al., “The C-terminal domain of RNA polymerase II couples mRNA processing to transcription,” Nature, vol. 385, no. 6614, pp. 357–360, 1997.

[35] Y. Hirose and J. L. Manley, “RNA polymerase II is an essential mRNA polyadenylation factor,” Nature, vol. 395, no. 6697, pp. 93–96, 1998.

[36] T. Maniatis and R. Reed, “An extensive network of coupling among gene expression machines,” Nature, vol. 416, no. 6880, pp. 499–506, 2002.

[37] M. J. Moore and N. J. Proudfoot, “Pre-mRNA processing reaches back to transcription and ahead to translation,” Cell, vol. 136, no. 4, pp. 688–700, 2009.

[38] M. de la Matta, C. Lafaille, and A. R. Kornblith, “First come, first served revisited: factors affecting the alternative splicing event have different effects on the relative rates of intron removal,” RNA, vol. 16, no. 5, pp. 904–912, 2010.

[39] A. Furger, J. M. O’Sullivan, A. Binnie, B. A. Lee, and N. J. Proudfoot, “Promoter proximal splice sites enhance transcription,” Genes and Development, vol. 16, no. 21, pp. 2792–2799, 2002.

[40] J. P. Fededa and A. R. Kornblith, “A splicing regulator promotes transcriptional elongation,” Nature Structural and Molecular Biology, vol. 15, no. 8, pp. 779–781, 2008.

[41] Y. W. Fong and Q. Zhou, “Stimulatory effects of splicing factors on transcriptional elongation,” Nature, vol. 414, no. 6866, pp. 929–933, 2001.

[42] S. Lin, G. Coutinho-Mansfield, D. Wang, S. Pandit, and X. D. Fu, “The splicing factor SC35 has an active role in transcriptional elongation,” Nature Structural and Molecular Biology, vol. 15, no. 8, pp. 819–826, 2008.
[43] K. Y. Kwek, S. Murphy, A. Furger et al., “U1 snRNA associates with TFIIH and regulates transcriptional initiation,” *Nature Structural Biology*, vol. 9, no. 11, pp. 800–805, 2002.

[44] C. K. Damgaard, S. Kahns, S. Lykke-Andersen, T. H. Jensen, and J. Kjems, “A 5′ splice site enhances the recruitment of basal transcription initiation factors in vivo,” *Molecular Cell*, vol. 29, no. 2, pp. 271–278, 2008.

[45] R. D. Alexander, S. A. Innocente, J. D. Barrass, and J. D. Beggs, “Splicing-dependent RNA polymerase pausing in yeast,” *Molecular Cell*, vol. 40, no. 4, pp. 582–593, 2010.

[46] F. Carrillo Oesterreich, S. Preibisch, and K. M. Neugebauer, “Global analysis of nascent RNA reveals transcriptional pausing in terminal exons,” *Molecular Cell*, vol. 40, no. 4, pp. 571–581, 2010.

[47] Y. Brody, N. Neufeld, N. Bieberstein et al., “The in vivo kinetics of RNA polymerase II elongation during co-transcriptional splicing,” *PLoS Biology*, vol. 9, no. 1, Article ID e1000573, 2011.

[48] J. Y. Ip, D. Schmidt, Q. Pan et al., “Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation,” *Genome Research*, vol. 21, no. 3, pp. 390–401, 2011.

[49] G. E. May, O. Sara, C. J. McManus, and B. R. Graveley, “Competing RNA secondary structures are required for mutually exclusive splicing of the Dscam exon 6 cluster,” RNA, vol. 17, no. 2, pp. 222–229, 2011.

[50] J. T. Witten and J. Ule, “Understanding splicing regulation through RNA splicing maps,” *Trends in Genetics*, vol. 27, no. 3, pp. 89–97, 2011.

[51] Y. Yang, L. Zhan, W. Zhang et al., “RNA secondary structure in mutually exclusive splicing,” *Nature Structural and Molecular Biology*, vol. 18, pp. 159–168, 2011.

[52] P. Cramer, C. G. Pesce, F. E. Baralle, and A. R. Kornblitt, “Functional association between promoter structure and transcript alternative splicing,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 21, pp. 11456–11460, 1997.

[53] P. Cramer, J. F. Cáceres, D. Cazalla et al., “Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer,” *Molecular Cell*, vol. 4, no. 2, pp. 251–258, 1999.

[54] D. Auboeuf, A. Höning, S. M. Berget, and B. W. O’Malley, “Coordinate regulation of transcription and splicing by steroid receptor coregulators,” *Science*, vol. 298, no. 5592, pp. 416–419, 2002.

[55] F. Pagani, C. Stuani, E. Zuccato, A. R. Kornblitt, and F. E. Baralle, “Promoter architecture modulates CFTR exon 9 skipping,” *Journal of Biological Chemistry*, vol. 278, no. 3, pp. 1511–1517, 2003.

[56] N. D. Robson-Dixon and M. A. Garcia-Blanco, “MAZ elements alter transcription elongation and silencing of the fibroblast growth factor receptor 2 exon IIIb,” *Journal of Biological Chemistry*, vol. 279, no. 28, pp. 29075–29084, 2004.

[57] G. Adami and L. E. Babiss, “DNA template effects on RNA splicing: two copies of the same gene in the same nucleus are processed differently,” *The EMBO Journal*, vol. 10, no. 11, pp. 3457–3465, 1991.

[58] G. Nogués, S. Kadener, P. Cramer, D. Bentley, and A. R. Kornblitt, “Transcriptional activators differ in their abilities to control alternative splicing,” *Journal of Biological Chemistry*, vol. 277, no. 45, pp. 43110–43114, 2002.

[59] D. Auboeuf, D. H. Dowhan, X. Li et al., “CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing,” *Molecular and Cellular Biology*, vol. 24, no. 1, pp. 442–453, 2004.

[60] G. C. Roberts, C. Gooding, H. Y. Mak, N. J. Proudfoot, and C. W. J. Smith, “Co-transcriptional commitment to alternative splice site selection,” *Nucleic Acids Research*, vol. 26, no. 24, pp. 5568–5572, 1998.

[61] M. de la Mata, C. R. Alonso, S. Kadener et al., “A slow RNA polymerase II affects alternative splicing in vivo,” *Molecular Cell*, vol. 12, no. 2, pp. 525–532, 2003.

[62] A. L. Greenleaf, “Positive patches and negative noodles: linking RNA processing to transcription?” *Trends in Biochemical Sciences*, vol. 18, no. 4, pp. 117–119, 1993.

[63] D. L. Bentley, “Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors,” *Current Opinion in Cell Biology*, vol. 17, no. 3, pp. 251–256, 2005.

[64] M. de la Mata and A. R. Kornblitt, “RNA polymerase II C-terminal domain mediates regulation of alternative splicing by SRp20,” *Nature Structural and Molecular Biology*, vol. 13, no. 11, pp. 973–980, 2006.

[65] M. J. Muñoz, M. de la Mata, and A. R. Kornblitt, “The carboxy terminal domain of RNA polymerase II and alternative splicing,” *Trends in Biochemical Sciences*, vol. 35, no. 9, pp. 497–504, 2010.

[66] T. Misteli and D. L. Spector, “RNA polymerase II targets pre-mRNA splicing factors to transcription sites in vivo,” *Molecular Cell*, vol. 3, no. 6, pp. 697–705, 1999.

[67] A. R. Kornblitt, “Coupling transcription and alternative splicing,” *Advances in Experimental Medicine and Biology*, vol. 623, pp. 175–189, 2007.

[68] N. J. Fuda, M. B. Ardehali, and J. T. Lis, “Defining mechanisms that regulate RNA polymerase II transcription in vivo,” *Nature*, vol. 461, no. 7261, pp. 186–192, 2009.

[69] L. P. Eperon, I. R. Graham, A. D. Griffiths, and I. C. Eperon, “Effects of RNA secondary structure on alternative splicing of Pre-mRNA: is folding limited to a region behind the transcribing RNA polymerase?” *Cell*, vol. 54, no. 3, pp. 393–401, 1988.

[70] S. Kadener, P. Cramer, G. Noguès et al., “Antagonistic effects of T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing,” *The EMBO Journal*, vol. 20, no. 20, pp. 5759–5768, 2001.

[71] S. Kadener, J. P. Fededa, M. Rosbash, and A. R. Kornblitt, “Regulation of alternative splicing by a transcriptional enhancer through RNA pol II elongation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 12, pp. 8185–8190, 2002.

[72] K. J. Howe, C. M. Kane, and M. Ares, “Perturbation of transcription elongation influences the fidelity of internal exon inclusion in Saccharomyces cerevisiae,” *RNA*, vol. 9, no. 8, pp. 993–1006, 2003.

[73] M. J. Muñoz, M. S. P. Santangelo, M. P. Paronetto et al., “DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation,” *Cell*, vol. 137, no. 4, pp. 708–720, 2009.

[74] M. Aebi and C. Weissman, “Precision and orderliness in splicing,” *Trends in Genetics*, vol. 3, no. 4, pp. 102–107, 1987.

[75] M. Alló, V. Buggiano, J. P. Fededa et al., “Control of alternative splicing through siRNA-mediated transcriptional gene silencing,” *Nature Structural and Molecular Biology*, vol. 16, no. 7, pp. 717–724, 2009.

[76] I. E. Schor, N. Rascovan, F. Pelisch, M. Alió, and A. R. Kornblitt, “Neuronal cell depolarization induces intragenic
[77] R. Andersson, E. Enroth, A. Rada-Iglesias, C. Wadelius, and J. Komorowski, “Nucleosomes are well positioned in exons and carry characteristic histone modifications,” *Genome Research*, vol. 19, no. 10, pp. 1732–1741, 2009.

[78] P. Kolasinska-Zwierz, T. Down, I. Latorre, T. Liu, X. S. Liu, and J. Ahringer, “Differential chromatin marking of introns and expressed exons by H3K36me3,” *Nature Genetics*, vol. 41, no. 3, pp. 376–381, 2009.

[79] S. Nahkuri, R. J. Taft, and J. S. Mattick, “Nucleosomes are preferentially positioned at exons in somatic and sperm cells,” *Cell Cycle*, vol. 8, no. 20, pp. 3420–3424, 2009.

[80] S. Schwartz, E. Meshorer, and G. Ast, “Chromatin organization marks exon-intron structure,” *Nature Structural and Molecular Biology*, vol. 16, no. 9, pp. 990–995, 2009.

[81] N. Spies, C. B. Nielsen, R. A. Padgett, and C. B. Burge, “Biased chromatin signatures around polyadenylation sites and exons,” *Molecular Cell*, vol. 36, no. 2, pp. 243–254, 2009.

[82] H. Tilgner, C. Nikolaou, S. Althammer et al., “Nucleosome positioning as a determinant of exon recognition,” *Nature Structural and Molecular Biology*, vol. 16, no. 9, pp. 996–1001, 2009.

[83] R. K. Chodavarapu, S. Feng, Y. V. Bernatavichute et al., “Relationship between nucleosome positioning and DNA methylation,” *Nature*, vol. 466, no. 7304, pp. 388–392, 2010.

[84] P. Dhami, P. Saffrey, A. W. Bruce et al., “Complex exon-intron marking by histone modifications is not determined solely by nucleosome distribution,” *PLoS One*, vol. 5, no. 8, Article ID e12339, 2010.

[85] M. K. Sakharkar, V. T. K. Chow, and P. Kangueane, “Distributions of exons and introns in the human genome,” *In Silico Biology*, vol. 4, no. 4, pp. 387–393, 2004.

[86] K. L. Fox-Walsh, Y. Dou, B. J. Lam, S. P. Hung, P. F. Baldi, and K. J. Hertel, “The architecture of pre-mRNAs affects mechanisms of splice-site pairing,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 45, pp. 16176–16181, 2005.

[87] S. M. Berget, “Exon recognition in vertebrate splicing,” *Journal of Biological Chemistry*, vol. 270, no. 6, pp. 2411–2414, 1995.

[88] A. S. Brodsky, C. A. Meyer, I. A. Swinburne et al., “Genomic mapping of RNA polymerase II reveals sites of cotranscriptional regulation in human cells,” *Genome Biology*, vol. 6, no. 8, p. R64, 2005.

[89] C. Hodges, L. Bintu, L. Lukbowska, M. Kashlev, and C. Bustamante, “Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II,” *Science*, vol. 325, no. 5940, pp. 626–628, 2009.

[90] L. S. Churchman and J. S. Weissman, “Nascent transcript sequencing visualizes transcription at nucleotide resolution,” *Nature*, vol. 469, no. 7330, pp. 368–373, 2011.

[91] E. Batsché, M. Yaniv, and C. Muchardt, “The human SWI/SNF subunit Brm is a regulator of alternative splicing,” *Nature Structural and Molecular Biology*, vol. 13, no. 1, pp. 22–29, 2006.

[92] M. Alló and A. R. Kornblitt, “Gene silencing: small RNAs control RNA polymerase II elongation,” *Current Biology*, vol. 20, no. 17, pp. R704–R707, 2010.

[93] E. Hodges, A. D. Smith, J. Kendall et al., “High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing,” *Genome Research*, vol. 19, no. 9, pp. 1593–1605, 2009.

[94] F. C. Oesterreich, N. Bieberstein, and K. M. Neugebauer, “Pause locally, splice globally,” *Trends in Cell Biology*, vol. 21, no. 6, pp. 328–335, 2011.

[95] R. J. Sims III, S. Millhouse, C. F. Chen et al., “Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing,” *Molecular Cell*, vol. 28, no. 4, pp. 665–676, 2007.

[96] R. F. Luco, Q. Pan, K. Tominaga, B. J. Blencowe, O. M. Pereira-Smith, and T. Misteli, “Regulation of alternative splicing by histone modifications,” *Science*, vol. 327, no. 5968, pp. 996–1000, 2010.

[97] A. Hanamura, J. F. Cáceres, A. Mayeda, B. R. Franka, and A. R. Krainer, “Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors,” *RNA*, vol. 4, no. 4, pp. 430–444, 1998.

[98] T. Xiao, H. Hall, K. O. Kizer et al., “Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast,” *Genes and Development*, vol. 17, no. 5, pp. 654–663, 2003.

[99] J. S. Lee and A. Shilatifard, “A site to remember: H3K36 methylation a mark for histone deacetylation,” *Mutation Research*, vol. 618, no. 1-2, pp. 130–134, 2007.

[100] S. Kishore and S. Stamm, “The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C,” *Science*, vol. 311, no. 5758, pp. 230–232, 2006.

[101] A. Khanna and S. Stamm, “Regulation of alternative splicing by short non-coding nuclear RNAs,” *RNA Biology*, vol. 7, no. 4, pp. 480–485, 2010.